Co-occurrence of symptoms after radiochemotherapy in locally advanced cervix cancer patients: a cluster analysis

References

• Pötter R, Tanderup K, Schmid MP, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 2021;22(4):538–547. doi: 10.1016/s1470-2045(20)30753-1.
   PubMed Web of Science ®Google Scholar
• Hande V, Chopra S, Kalra B, et al. Point-a vs. volume-based brachytherapy for the treatment of cervix cancer: a meta-analysis. Radiother Oncol. 2022; 170:70–78. doi: 10.1016/j.radonc.2022.02.038.
   PubMed Web of Science ®Google Scholar
• Vittrup AS, Kirchheiner K, Pötter R, et al. Overall severe morbidity after chemo-radiation therapy and magnetic resonance imaging-guided adaptive brachytherapy in locally advanced cervical cancer: results from the EMBRACE-I study. Int J Radiat Oncol Biol Phys. 2023;116(4):807–824. doi: 10.1016/j.ijrobp.2023.01.002.
   PubMedGoogle Scholar
• Farnell DJ, Mandall P, Anandadas C, et al. Development of a patient-reported questionnaire for collecting toxicity data following prostate brachytherapy. Radiother Oncol. 2010;97(1):136–142. doi: 10.1016/j.radonc.2010.05.011.
   PubMed Web of Science ®Google Scholar
• Hatakeyama Y, Miyano I, Kataoka H, et al. Use of a latent topic model for characteristic extraction from health checkup questionnaire data. Methods Inf Med. 2015;54(6):515–521. doi: 10.3414/ME15-01-0023.
   PubMed Web of Science ®Google Scholar
• Hockenberry M, Hooke MC. Symptom clusters in children with cancer. Semin Oncol Nurs. 2007;23(2):152–157. doi: 10.1016/j.soncn.2007.01.001.
   PubMedGoogle Scholar
• Kim HJ, Abraham I, Malone PS. Analytical methods and issues for symptom cluster research in oncology. Curr Opin Support Palliat Care. 2013; 7(1):45–53. doi: 10.1097/spc.0b013e32835bf28b.
   PubMed Web of Science ®Google Scholar
• Thor M, Olsson CE, Oh JH, et al. Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer. Acta Oncol. 2015;54(9):1326–1334. doi: 10.3109/0284186X.2015.1063779.
   PubMed Web of Science ®Google Scholar
• Hwang KH, Cho OH, Yoo YS. Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life. Eur J Oncol Nurs. 2016; 21:215–222. doi: 10.1016/j.ejon.2015.10.007.
   PubMed Web of Science ®Google Scholar
• Matzka M, Köck-Hódi S, Jahn P, et al. Relationship among symptom clusters, quality of life, and treatment-specific optimism in patients with cancer. Support Care Cancer. 2018; 226(8):2685–2693. doi: 10.1007/s00520-018-4102-8.
   PubMed Web of Science ®Google Scholar
• Powell VD, Kumar N, Galecki AT, et al. Bad company: loneliness longitudinally predicts the symptom cluster of pain, fatigue, and depression in older adults. J Am Geriatr Soc. 2022;70(8):2225–2234. doi: 10.1111/jgs.17796.
   PubMed Web of Science ®Google Scholar
• Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncology Nursing Forum. 2001;28(3):465–470.
   PubMedGoogle Scholar
• Kim HJ, McGuire DB, Tulman L, et al. Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs. 2005;28(4):270–282. doi: 10.1097/00002820-200507000-00005.
   PubMed Web of Science ®Google Scholar
• Kirkova J, Walsh D, Aktas A, et al. Cancer symptom clusters: old concept but new data. Am J Hosp Palliat Care. 2010;27(4):282–288. doi: 10.1177/1049909110364048.
   PubMed Web of Science ®Google Scholar
• Palagini L, Miniati M, Riemann D, et al. Insomnia, fatigue, and depression: theoretical and clinical implications of a self-reinforcing feedback loop in cancer. Clin Pract Epidemiol Ment Health. 2021;17(1):257–263. doi: 10.2174/1745017902117010257.
   PubMedGoogle Scholar
• Cherwin CH. Gastrointestinal symptom representation in cancer symptom clusters: a synthesis of the literature. Oncol Nurs Forum. 2012; 39(2):157–165. doi: 10.1188/12.ONF.157-165.
   PubMed Web of Science ®Google Scholar
• Li Y, Li X, Mao C, et al. Symptom clusters in head and neck cancer patients with endotracheal tube: which symptom clusters are independently associated with health-related quality of life? Eur J Oncol Nurs. 2020;48:101819. doi: 10.1016/j.ejon.2020.101819.
   PubMed Web of Science ®Google Scholar
• Xiao C. The state of science in the study of cancer symptom clusters. Eur J Oncol Nurs. 2010;14(5):417–434. doi: 10.1016/j.ejon.2010.05.011.
   PubMed Web of Science ®Google Scholar
• Kirkova J, Aktas A, Walsh D, et al. Cancer symptom clusters: clinical and research methodology. J Palliat Med. 2011;14(10):1149–1166. doi: 10.1089/jpm.2010.0507.
   PubMed Web of Science ®Google Scholar
• Murtagh F, Contreras P. Algorithms for hierarchical clustering: an overview. WIREs Data Min & Knowl. 2012; 12(1):86–97. doi: 10.1002/widm.53.
   Web of Science ®Google Scholar
• Miaskowski C. Future directions in symptom cluster research. Semin Oncol Nurs. 2016;32(4):405–415. doi: 10.1016/j.soncn.2016.08.006.
   PubMed Web of Science ®Google Scholar
• Pachman DR, Barton DL, Swetz KM, et al. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012;30(30):3687–3696. doi: 10.1200/jco.2012.41.7238.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom KL. Cancer symptom cluster management. Semin Oncol Nurs. 2016; 32(4):373–382. doi: 10.1016/j.soncn.2016.08.004.
   PubMed Web of Science ®Google Scholar
• Vittrup AS, Kirchheiner K, Fokdal LU, et al. Reporting of late morbidity after radiation therapy in large prospective studies: a descriptive review of the current status. Int J Radiat Oncol Biol Phys. 2019;105(5):957–967. doi: 10.1016/j.ijrobp.2019.08.040.
   PubMed Web of Science ®Google Scholar
• Kirchheiner K, Nout RA, Tanderup K, et al. Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study. Int J Radiat Oncol Biol Phys. 2014;89(1):88–95. doi: 10.1016/j.ijrobp.2014.01.032.
   PubMed Web of Science ®Google Scholar
• Mazeron R, Fokdal LU, Kirchheiner K, et al. Dose–volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: results from the prospective multicenter EMBRACE study. Radiother Oncol. 2016;120(3):412–419. doi: 10.1016/j.radonc.2016.06.006.
   PubMed Web of Science ®Google Scholar
• Fokdal L, Pötter R, Kirchheiner K, et al. Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Radiother Oncol. 2018;127(3):423–430. doi: 10.1016/j.radonc.2018.05.002.
   PubMed Web of Science ®Google Scholar
• Jensen NBK, Pötter R, Kirchheiner K, et al. Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: physician- and patient reported outcome from the EMBRACE study. Radiother Oncol. 2018;127(3):431–439. doi: 10.1016/j.radonc.2018.05.016.
   PubMed Web of Science ®Google Scholar
• Smet S, Pötter R, Haie-Meder C, et al. Fatigue, insomnia and hot flashes after definitive radiochemotherapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study. Radiother Oncol. 2018;127(3):440–448. doi: 10.1016/j.radonc.2018.03.009.
   PubMed Web of Science ®Google Scholar
• Spampinato S, Jensen NB, Pötter R, et al. Severity and persistency of late gastrointestinal morbidity in locally advanced cervical cancer: lessons learned from EMBRACE-I and implications for the future. Int J Radiat Oncol Biol Phys. 2022;112(3):681–693. doi: 10.1016/j.ijrobp.2021.09.055.
   PubMed Web of Science ®Google Scholar
• Kirchheiner K, Nout RA, Lindegaard JC, et al. Dose–effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiother Oncol. 2016;118(1):160–166. doi: 10.1016/j.radonc.2015.12.025.
   PubMed Web of Science ®Google Scholar
• Spampinato S, Fokdal LU, Pötter R, et al. Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: an EMBRACE analysis. Radiother Oncol. 2021;158:312–320. doi: 10.1016/j.radonc.2021.01.019.
   PubMedGoogle Scholar
• Smet S, Spampinato S, Pötter R, et al. Risk factors for late persistent fatigue after chemoradiotherapy in patients with locally advanced cervical cancer: an analysis from the EMBRACE-i study. Int J Radiat Oncol Biol Phys. 2022;112(5):1177–1189. doi: 10.1016/j.ijrobp.2021.11.022.
   PubMed Web of Science ®Google Scholar
• Spampinato S, Tanderup K, Lindegaard JC, et al. Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors. Radiother Oncol. 2023;181:109501. doi: 10.1016/j.radonc.2023.109501.
   PubMed Web of Science ®Google Scholar
• Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009;105(2):107–108. doi: 10.1016/j.ijgo.2009.02.009.
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 713(3):176–181. doi: 10.1016/s1053-4296(03)00031-6.
   PubMed Web of Science ®Google Scholar
• Wainer H, Messick S, editors. Principals of modern psychological measurement: a Festschrift for Frederic M. Lord (1st ed.). Routledge; 1983. doi: 10.4324/9780203056653.
   Google Scholar
• Kaiser HF. A second generation little jiffy. Psychometrika. 1970;35(4):401–415. doi: 10.1007/BF02291817.
   Web of Science ®Google Scholar
• Fayers P. Interpreting quality of life data. Eur J Cancer. 2001; 37(11):1331–1334. doi: 10.1016/s0959-8049(01)00127-7.
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J RStat Soci: series B. 1995;57:289–300.
   Web of Science ®Google Scholar
• Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10(7):718–726. doi: 10.1016/s1470-2045(09)70082-8.
   PubMed Web of Science ®Google Scholar
• Morris KA, Haboubi NY. Pelvic radiation therapy: between delight and disaster. World J Gastrointest Surg. 2015;7(11):279–288. doi: 10.4240/wjgs.v7.i11.279.
   PubMedGoogle Scholar
• Given B, Given C, Azzouz F, et al. Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nurs Res. 2001;50(4):222–232. doi: 10.1097/00006199-200107000-00006.
   PubMed Web of Science ®Google Scholar
• Gift AG, Stommel M, Jablonski A, et al. A Cluster of Symptoms Over Time in Patients With Lung Cancer. Nurs Res. 2003;52(6):393–400.doi: 10.1097/00006199-200311000-00007.
   Google Scholar
• Fox SW, Lyon D. Symptom clusters and quality of life in survivors of ovarian cancer. Cancer Nurs. 2007; 30(5):354–361. doi: 10.1097/01.ncc.0000290809.61206.ef.
   PubMed Web of Science ®Google Scholar
• Fox SW, Lyon DE. Symptom clusters and quality of life in survivors of lung cancer. Oncol Nurs Forum. 2006; 33(5):931–936. doi: 10.1188/06.ONF.931-936.
   PubMed Web of Science ®Google Scholar
• Hoffman AJ, Given BA, von Eye A, et al. Relationships among pain, fatigue, insomnia, and gender in persons with lung cancer. Oncol Nurs Forum. 2007;34(4):785–792. doi: 10.1188/07.ONF.785-792.
   PubMed Web of Science ®Google Scholar
• Feng LR, Fuss T, Dickinson K, et al. Co-occurring symptoms contribute to persistent fatigue in prostate cancer. Oncology. 2019;96(4):183–191. doi: 10.1159/000494620.
   PubMed Web of Science ®Google Scholar
• Gaston-Johansson F, Fall-Dickson JM, Bakos AB, et al. Fatigue, pain, and depression in pre-autotransplant breast cancer patients. Cancer Pract. 1999;7(5):240–247. doi: 10.1046/j.1523-5394.1999.75008.x.
   PubMedGoogle Scholar
• Liu L, Fiorentino L, Natarajan L, et al. Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy. Psychooncology. 2009;18(2):187–194. doi: 10.1002/pon.1412.
   PubMed Web of Science ®Google Scholar
• Fiorentino L, Rissling M, Liu L, et al. The symptom cluster of sleep, fatigue and depressive symptoms in breast cancer patients: severity of the problem and treatment options. Drug Discov Today Dis Models. 2011;8(4):167–173. Available from doi: 10.1016/j.ddmod.2011.05.001.
   PubMedGoogle Scholar
• Trudel-Fitzgerald C, Savard J, Ivers H. Which symptoms come first? exploration of temporal relationships between cancer-related symptoms over an 18-month period. Ann Behav Med. 2013; 45(3):329–337. doi: 10.1007/s12160-012-9459-1.
   PubMed Web of Science ®Google Scholar
• Bonanni E, Schirru A, Perri MCD, et al. Insomnia and hot flashes. Maturitas. 2019;126:51–54. doi: 10.1016/j.maturitas.2019.05.001.
   PubMed Web of Science ®Google Scholar
• Keramida K, Kostoulas A. Dyspnoea in oncological patients: a brain teaser. Eur Cardiol. 2023;18:e03. doi: 10.15420/ecr.2021.62.
   PubMed Web of Science ®Google Scholar
• Bonhof CS, Poll-Franse LV, Vissers PA, et al. Anxiety and depression mediate the association between chemotherapy-induced peripheral neuropathy and fatigue: results from the population-based PROFILES registry. Psychooncology. 2019;28(9):1926–1933. doi: 10.1002/pon.5176.
   PubMed Web of Science ®Google Scholar
• Fallon M. Neuropathic pain in cancer. Br J Anaesth. 2013; 111(1):105–111. doi: 10.1093/bja/aet208.
   PubMed Web of Science ®Google Scholar
• Hong J, Tian J, Wu L. The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep sisturbance in cancer patients. Curr Oncol. 2014; 21(4):174–180. doi: 10.3747/co.21.1984.
   PubMed Web of Science ®Google Scholar
• Vittrup AS, Tanderup K, Bentzen SM, et al. Persistence of late substantial patient-reported symptoms (lapers) after radiochemotherapy including image guided adaptive brachytherapy for locally advanced cervical cancer: a report from the embrace study. Int J Radiat Oncol Biol Phys. 2021; 1109(1):161–173. doi: 10.1016/j.ijrobp.2020.08.044.
   PubMed Web of Science ®Google Scholar
• Maranzano E. Radiation-induced emesis: a problem with many open questions. Tumori J. 2001; 87(4):213–218. doi: 10.1177/030089160108700401.
   PubMed Web of Science ®Google Scholar
• Poon M, Dennis K, DeAngelis C, et al. Symptom clusters of gastrointestinal cancer patients undergoing radiotherapy using the functional living index—emesis (FLIE) quality-of-life tool. Support Care Cancer. 2015;23(9):2589–2598. Available from doi: 10.1007/s00520-015-2617-9.
   PubMed Web of Science ®Google Scholar
• Yee C, Drost L, Zhang L, et al. Impact of radiation-induced nausea and vomiting on quality of life. Support Care Cancer. 2018;26(11):3959–3966. doi: 10.1007/s00520-018-4286-y.
   PubMed Web of Science ®Google Scholar
• Spampinato S, Tanderup K, Marinovskij E, et al. Mri-based contouring of functional Sub-structures of the lower urinary tract in gynaecological radiotherapy. Radiother Oncol. 2020;145:117–124. doi: 10.1016/j.radonc.2019.12.011.
   PubMed Web of Science ®Google Scholar
• Jensen NBK, Pötter R, Spampinato S, et al. Dose-volume effects and risk factors for late diarrhea in cervix cancer patients after radiochemotherapy with image guided adaptive brachytherapy in the EMBRACE i study. Int J Radiat Oncol Biol Phys. 2021;109(3):688–700. doi: 10.1016/j.ijrobp.2020.10.006.
   PubMed Web of Science ®Google Scholar
• Kirchheiner K, Pötter R, Nout RA, et al. Late, persistent, substantial, treatment-related symptoms after radiation therapy ({LAPERS}): a new method for longitudinal analysis of late morbidity{—}applied in the {EMBRACE} study. Int J Radiat Oncol Biol Phys. 2020; 2106(2):300–309. doi: 10.1016/j.ijrobp.2019.10.027.
   PubMed Web of Science ®Google Scholar
• Kirchheiner K, Smet S, Jürgenliemk-Schulz IM, et al. Impact of vaginal symptoms and hormonal replacement therapy on sexual outcomes after definitive chemoradiotherapy in patients with locally advanced cervical cancer: results from the EMBRACE-I study. Int J Radiat Oncol Biol Phys. 2022;112(2):400–413. doi: 10.1016/j.ijrobp.2021.08.036.
   PubMed Web of Science ®Google Scholar
• Perez CA, Grigsby PW, Lockett MA, et al. Radiation therapy morbidity in carcinoma of the uterine cervix: dosimetric and clinical correlation. Int J Radiat Oncol Biol Phys. 1999;44(4):855–866. doi: 10.1016/s0360-3016(99)00111-x.
   PubMed Web of Science ®Google Scholar
• Georg P, Boni A, Ghabuous A, et al. Time course of late rectal-and urinary bladder side effects after MRI-guided adaptive brachytherapy for cervical cancer. Strahlenther Onkol. 2013;189(7):535–540. doi: 10.1007/s00066-013-0365-7.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Ohno T, Noguchi W, et al. Psychological distress and quality of life in cervical cancer survivors after radiotherapy. Int J Gynecol Cancer. 2009;19(7):1264–1268. doi: 10.1111/IGC.0b013e3181a3e124.
   PubMed Web of Science ®Google Scholar
• Fernandes A, Bhuva NJ, Taylor A. Management of toxicities following pelvic irradiation for gynaecological cancers. Curr Opin Oncol. 2015; 27(5):405–411. doi: 10.1097/cco.0000000000000215.
   PubMed Web of Science ®Google Scholar
• Pasek M, Suchocka L, Osuch-Pȩcak G, et al. Longitudinal health-related quality of life study among cervical cancer patients treated with radiotherapy. J Clin Med. 2021;10(2):226. doi: 10.3390/jcm10020226.
   PubMed Web of Science ®Google Scholar
• Miaskowski C, Aouizerat BE, Dodd M, et al. Conceptual issues in symptom clusters research and their implications for quality-of-life assessment in patients with cancer. JNCI Monographs. 2007;2007(37):39–46. doi: 10.1093/jncimonographs/lgm003.
   Google Scholar
• Hobbs BP, Thall PF, Lin SH. Bayesian group sequential clinical trial design using total toxicity burden and progression-free survival. Royal Stat Soc Series C, Appl Stat. 2016;65(2):273–297. doi: 10.1111/rssc.12117.
   PubMed Web of Science ®Google Scholar
• Ranjan N, Chopra S, Mangaj A, et al. Months and severity score (moses) in a phase iii trial (parcer): a new comprehensive method for reporting adverse events in oncology clinical trials. eClinicalMedicine. 2022;47:101390. doi: 10.1016/j.eclinm.2022.101390.
   PubMedGoogle Scholar